101
Participants
Start Date
November 30, 2016
Primary Completion Date
January 25, 2024
Study Completion Date
January 25, 2024
BMS-986207
Specified dose on specified days
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution - 0006, Nedlands
Local Institution - 0003, New York
Local Institution - 0009, Pittsburgh
Local Institution - 0012, Philadelphia
Local Institution - 0002, Philadelphia
Local Institution - 0010, Salt Lake City
Local Institution - 0020, Singapore
Local Institution - 0018, Craiova
Local Institution - 0016, Cluj-Napoca
Local Institution - 0015, Florești
Local Institution - 0005, Chuo-ku
Local Institution - 0004, Kashiwa-shi
Local Institution - 0021, Santiago
Local Institution - 0001, Hackensack
Local Institution - 0023, CABA
Local Institution - 0019, Córdoba
Local Institution - 0022, Buenos Aires
Local Institution - 0008, Ottawa
Local Institution - 0007, Toronto
Local Institution - 0017, Bucharest
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY